Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Chemogenomics Reveals New Synergies
Refined Strategies Shed Light on Biological Processes and Improve Drug Selectivity and Safety Profiling
- Although not everyone agrees on the definition of chemogenomics, most believe the field holds great promise for the pharmaceutical industry. In its broadest sense, chemogenomics describes how a chemical or family of compounds affects the genome. At the end of the day, this systematic approach combined with genomic targets ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.